12.33
+0.72(+6.20%)
Currency In USD
Address
11711 N. Meridian Street
Carmel, IN 46032
United States of America
Phone
(317) 659-0200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
43
First IPO Date
January 14, 2000
| Name | Title | Pay | Year Born |
| Mr. Peter Kent Hawryluk MBA | Chief Executive Officer, President & Director | 788,300 | 1969 |
| Dr. Salomon Azoulay M.D. | Chief Medical Officer | 520,512 | 1958 |
| Mr. Richard B. Bartram CPA | Chief Financial Officer | 642,001 | 1981 |
| Ms. Michelle Graham | Chief Human Resources Officer | 0 | 1967 |
| Mr. Mark Hope | Senior Vice President of Regulatory & Quality | 0 | N/A |
| Dr. Chatan Charan Ph.D. | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls | 0 | N/A |
| Mr. Matt Gambino | Vice President of Marketing | 0 | N/A |
| Dr. Michael A. Dorato DABT, Ph.D. | Senior Vice President of Discovery & Non-Clinical Development | 0 | N/A |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.